small molecule

MACITENTAN

Loss of exclusivityDecember 2026FDA regulatory exclusivity expiry

CompanyTeva →See this company's full patent-cliff portfolio

Drug detail

Brand name	MACITENTAN
Active ingredient	MACITENTAN
Strength	10MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2026
Marketing status	RX

Regulatory exclusivity

Code	Expires
PC	December 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Regulatory exclusivity

More from Teva